Skip to main content
EyePoint Pharmaceuticals, Inc. logo

EyePoint Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · EYPT ISIN · US74440J1016 LEI · 549300QE1RU34T50MR69 US Manufacturing
Open in API
Filings indexed 1,019 across all filing types
Latest filing 2015-07-27 Director's Dealing
Country US United States of America
Listing US EYPT

About EyePoint Pharmaceuticals, Inc.

https://eyepointpharma.com/

EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for serious retinal diseases. The company leverages its proprietary Durasert E™ technology, a bio-erodible platform for sustained intraocular drug delivery, to create durable therapies. Its lead investigational product, DURAVYU™ (EYP-1901), combines the tyrosine kinase inhibitor vorolanib with the Durasert E™ system for the potential treatment of VEGF-mediated retinal diseases. The company's goal is to improve patient outcomes and reduce treatment burden by providing long-lasting treatments for chronic eye conditions.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2015-07-27 English
FORM 4 SUBMISSION
Director's Dealing
2015-07-27 English
FORM 10-Q
Interim / Quarterly Report 9M 2015
2015-05-08 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions Item 2.02, which is "Results of Operations and Financial Condition," and states that the company issued a press release announcing its third quarter fiscal year 2015 results. The document includes a press release as an exhibit but does not contain detailed financial statements or comprehensive financial analysis itself. The length is 2655 characters, which is relatively short and consistent with a brief announcement rather than a full financial report. According to the rules, a document that announces or furnishes a press release about quarterly results without containing the full financial data should be classified as an Earnings Release (ER). The document is not a full quarterly report (IR), nor an annual report (10-K), nor a management discussion (MDA). Therefore, the best classification is Earnings Release (ER).
2015-05-08 English
SCHEDULE 13D AMENDMENT
Major Shareholding Notification
2015-05-01 English
SC 13G/A
Major Shareholding Notification
2015-02-17 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.